Xenon Pharmaceuticals (XENE) Other financing activities (2015 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Other financing activities of $5.5 million for Q1 2026, up 376.72% year-over-year from $1.2 million in Q1 2025, and up 295.89% quarter-over-quarter from $1.4 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Other financing activities (2015 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Other financing activities for 11 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 376.72% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $9.3 million (up 676.13% YoY), while the FY2025 annual figure was $5.0 million, up 10457.45% from the prior year.
- Other financing activities grew to $5.5 million in Q1 2026 per XENE's latest filing, from $1.4 million in the prior quarter.
- Across five years, Other financing activities topped out at $5.5 million in Q1 2026 and bottomed at $6000.0 in Q4 2022.
- Historically, Other financing activities has averaged $1.5 million across 4 years, with a median of $1.2 million in 2025.
- Annual changes were most pronounced in 2022 — Other financing activities plunged 60.0% — and 2025, when it soared 2848.94%.
- Xenon Pharmaceuticals' Other financing activities stood at $6000.0 in 2022, then soared by 683.33% to $47000.0 in 2024, then jumped by 2848.94% to $1.4 million in 2025, then surged by 295.89% to $5.5 million in 2026.
- Business Quant data shows XENE's Other financing activities at $5.5 million in Q1 2026, $1.4 million in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26,000.00 |
| Jun 30, 2026 | 26,000.00 |
| Mar 31, 2026 | 5.49 Mn |
| Mar 31, 2026 | 5.49 Mn |
| Dec 31, 2025 | 1.39 Mn |
| Dec 31, 2025 | 1.39 Mn |
| Sep 30, 2025 | 2.36 Mn |
| Sep 30, 2025 | 2.36 Mn |
| Jun 30, 2025 | 65,000.00 |
| Jun 30, 2025 | 65,000.00 |
| Mar 31, 2025 | 1.15 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 47,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Dec 31, 2022 | 6,000.00 |
| Dec 31, 2022 | 6,000.00 |
| Dec 31, 2021 | 15,000.00 |
| Dec 31, 2021 | 15,000.00 |
| Sep 30, 2021 | 28,000.00 |
| Sep 30, 2021 | 28,000.00 |